Xin Sun

Xin Sun

Directeur/Bestuurslid bij EVEREST MEDICINES LIMITED
45 jaar
Health Technology
Consumer Services
Finance

Profiel

Xin Sun is currently Chairman-Supervisory Board at Scivita Medical Technology Co., Ltd. since 2021.
Mr. Sun is Non-Executive Director at MicroPort Cardiac Rhythm Management International Ltd. since 2023, Everest Medicines Ltd. since 2025, and NeuroGen Pharma Ltd. since 2026.
Mr. Sun is Managing Director at CBC Group Co., Ltd. and Hillhouse Capital Management Co Ltd since 2017.
Mr. Sun is also a Research Associate at Genentech, Inc. Former roles include Non-Executive Director at Luye Pharma Group Ltd. from 2021 to 2023, Non-Executive Director at Shanghai MicroPort MedBot (Group) Co., Ltd. from 2021 to 2023, and Vice President at Affinity Equity Partners (HK) Ltd. Education includes undergraduate degrees from Peking University in 2003 and The Trustees of Columbia University in The City of New York in 2013, a graduate degree from Duke University in 2006, and an MBA from Columbia Business School.

Actieve functies van Xin Sun

BedrijvenFunctieBegin
EVEREST MEDICINES LIMITED Directeur/Bestuurslid 11-12-2025
Voorzitter 22-06-2021
Directeur/Bestuurslid 17-07-2020
CBC Group Co., Ltd.
Corporate Officer/Principal -
Corporate Officer/Principal 01-01-2017
Corporate Officer/Principal -

Eerdere bekende functies van Xin Sun

BedrijvenFunctieEinde
SHANGHAI MICROPORT MEDBOT (GROUP) CO., LTD. Directeur/Bestuurslid 29-12-2023
LUYE PHARMA GROUP LTD. Directeur/Bestuurslid 06-12-2023
Corporate Officer/Principal -
Ervaring van Xin Sun in detail bekijken

Opleiding van Xin Sun

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

97

Eerstegraads connecties

13

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit13

Health Technology

Consumer Services

Consumer Services

Consumer Services

Finance

Health Technology

Consumer Services

Health Technology

CBC Group Co., Ltd.

Health Technology

Health Technology

Miscellaneous

Finance